We conducted a multicentre test-negative case–control study in 27 hospitals of 11 European countries to measure 2015/16 influenza vaccine effectiveness (IVE) against hospitalised influenza A(H1N1)pdm09 and B among people aged ≥ 65 years. Patients swabbed within 7 days after onset of symptoms compatible with severe acute respiratory infection were included. Information on demographics, vaccination and underlying conditions was collected. Using logistic regression, we measured IVE adjusted for potential confounders. We included 355 influenza A(H1N1)pdm09 cases, 110 influenza B cases, and 1,274 controls. Adjusted IVE against influenza A(H1N1)pdm09 was 42% (95% confidence interval (CI): 22 to 57), 48% (95% CI: 5 to 71), 43% (95% CI: 8 to 65) and 39% (95% CI: 7 to 60) in patients with diabetes mellitus, lung and heart disease, respectively. Adjusted IVE against influenza B was 52% (95% CI: 24 to 70). It was 62% (95% CI: 5 to 85), 60% (95% CI: 18 to 80) and 36% (95% CI: -23 to 67) in patients with diabetes mellitus, lung and heart disease, respectively. 2015/16 IVE estimates against hospitalised influenza in elderly people was moderate against influenza A(H1N1)pdm09 and B, including among those with diabetes mellitus, cancer, lung or heart diseases.

Background

Elderly populations, defined as those aged 65 years and above, and, more specifically, elderly people with underlying conditions, are at increased risk for hospitalisation due to influenza [1]. Influenza may also increase the severity of underlying chronic lung diseases, probably through inflammatory processes [2]. Viral pneumonia due to influenza seems to predispose to myocardial infarction, and congestive heart failures are more common during influenza seasons [3]. Patients with cancer treated with chemotherapy [4] and diabetic patients are more vulnerable to influenza. Their impaired immune response [5] could also affect host response to vaccination [6,7]. Evidence of
the effectiveness of influenza vaccination in preventing severe clinical outcomes was recently described as low or very low among elderly people [8], and among patients with cancer [9], diabetes mellitus [10], lung diseases [11][12], or cardiovascular diseases [13].

Despite the Council of the European Union and the World Health Organization’s (WHO) recommendations to annually vaccinate elderly people [14,15], influenza vaccine coverage among elderly people remains below the 75% target in most European countries [16].

In this context, post-marketing studies to estimate the influenza vaccine effectiveness (IVE) among elderly people are needed to inform about vaccination benefits for vaccinees, detect subgroups in which the vaccine performs less well and identify vaccine types that perform best. In 2015, to address this issue, the Integrated Monitoring of Vaccines in Europe plus (I-MOVE+) consortium initiated a network of hospitals across Europe to measure IVE against laboratory-confirmed hospitalised influenza among elderly people.

The WHO recommended to include in the 2015/16 trivalent influenza vaccine for the northern hemisphere an A/California/7/2009 (H1N1)pdm09-like virus, an A/Switzerland/9715293/2013 (H3N2)-like virus and a B/Phuket/3073/2013-like virus (Yamagata lineage) [17].

In the 2015/16 influenza season in Europe, influenza A(H1N1)pdm09 and influenza B (mainly Victoria lineage) viruses predominated [18]. We conducted a multicentre hospital-based test-negative design (TND) case–control study to measure the 2015/16 seasonal IVE against hospitalisation with influenza A(H1N1)pdm09 and influenza B among elderly people in Europe, by risk groups and for specific vaccine types.
Methods

Study sites and design
We set up a European network of 27 hospitals in 11 countries (Croatia, Finland, France, Hungary, Italy, Lithuania, the Netherlands, Poland, Portugal, Romania and Spain) (Figure 1), organised in 12 study sites (in Spain, Navarre region hospitals had their own coordination centre). Each study site adapted a generic protocol to their local setting [19,20]. Monitoring visits were organised to ensure the study was done similarly across hospitals. We conducted a multicentre TND case–control study.

Study period
In each study site, the study period started at least two weeks after the beginning of the vaccination campaign in the respective countries and lasted from the week of the first detection of a laboratory-confirmed case of influenza to the week of the last laboratory-confirmed case of influenza. We defined different study periods for influenza A(H1N1)pdm09 and B.

Study population
Our study population included all community dwelling patients aged 65 years and above who had no contraindication for influenza vaccination or previous laboratory-confirmed influenza in the season and agreed to participate. In the participating services of each hospital, patients admitted for clinical conditions that could be related to influenza were screened for eligibility. Study physicians, nurses or collaborating medical staff asked patients about onset of symptoms compatible with the definition of a severe acute respiratory infection (SARI) in the previous 7 days.

We defined a SARI case as a hospitalised patient with at least one systemic (fever or feverishness, malaise, headache, myalgia or deterioration of general or functional condition) and at least one respiratory sign or symptom (cough, sore throat or shortness of breath) at admission, or within 48 hours after admission.

Data collection
The hospital study teams swabbed patients meeting the SARI case definition. Specimens were tested by

Figure 2
Cases of severe acute respiratory infection with influenza A(H3N2), A(H1N1)pdm09, and B, and negative controls, I-MOVE+ study, Europe, influenza season 2015/16 (n = 504 casesa; n = 1,274 controls)

I-MOVE+: Integrated Monitoring of Vaccines in Europe plus; ISO: International Organisation for Standardisation; SARI: severe acute respiratory infection.

a Including two influenza A(H1N1)pdm09 and B co-infections and one influenza A(H3N2) and B co-infection.
RT-PCR and patients classified as influenza A(H1N1)pdm09 cases, influenza B cases, other influenza cases or controls if their specimens tested negative for any influenza virus.

The hospital study teams collected information on patients’ age and sex, influenza vaccination status including date and brand of the 2015/16 vaccine and the status in two previous seasons and underlying conditions listed for clinical risk groups recommended for influenza vaccination [21]. The underlying conditions included diabetes mellitus, obesity (defined as body mass index ≥ 30 kg/m²), cardiovascular conditions (such as congenital heart disease, congestive heart failure and coronary artery disease), lung diseases (such as chronic obstructive pulmonary disease, cystic fibrosis, asthma), renal and rheumatologic diseases, cancer, stroke, dementia and cirrhosis. Information on number of hospitalisations for underlying conditions in the previous 12 months, number of general practitioners (GP) visits in the previous three months, smoking status and functional impairment (based on Barthel index score [22]) was also collected.

Information on demographics and underlying conditions were collected from interviews with patients (or their relatives) and hospital and/or primary care databases. In study sites with no vaccination register, vaccination status was collected through interview with patients. For patients vaccinated or unable to provide their vaccination status, study sites called patients’ GP or pharmacists to retrieve vaccination status, date and brand (Table 1).

We defined patients as vaccinated with the 2015/16 influenza vaccine if they had been vaccinated at least 14 days before symptoms onset. Otherwise, they were considered as unvaccinated.

### Data analysis

We computed the IVE as (1 minus the odds ratio (OR) of vaccination between cases and controls) x 100. We performed a pooled one-stage analysis using the study site as a fixed effect and estimated IVE stratified on the presence of underlying conditions. All IVE estimates were adjusted for study site, date of SARI symptom onset and age modelled as restricted cubic splines with four knots (initial model). To adjust for additional potential confounders (sex, each group of underlying conditions, hospitalisation in the past year, more than one GP visit in the past 3 months, functional impairment, current smoking), we performed a multivariable analysis using an onward step by step modelling and analysing them as dichotomous variables. Patients with missing covariates were excluded from the analyses adjusted for these covariates. We retained in the model (full model) all covariates that changed the IVE estimate by 10% or more (relative change).

We grouped the vaccine brands in split virion, subunit or adjuvanted vaccines. To compute vaccine type-specific effectiveness, we restricted our analyses to

| Study site     | Number of hospitals | Vaccines used                      | Data sources | Source of information for vaccination status | Source of information for underlying conditions |
|----------------|---------------------|------------------------------------|--------------|----------------------------------------------|-----------------------------------------------|
| Croatia        | 1                   | Inactivated subunit                | I            | I; H                                         |
| Finland        | 2                   | Inactivated split                  | R; I; GP     | I; GP; H                                     |
| France         | 3                   | Inactivated subunit; inactivated    | I; P         | I; H                                         |
| Hungary        | 2                   | Adjuvanted                         | I; GP        | I; H                                         |
| Italy          | 3                   | Inactivated subunit; inactivated    | I; GP        | I; H                                         |
| Lithuania      | 2                   | Inactivated subunit                | I; GP        | I; H                                         |
| Navarre        | 3                   | Inactivated split                  | R            | I; GP; H                                     |
| The Netherlands| 1                   | Inactivated subunit; inactivated    | I            | I; H                                         |
| Poland         | 3                   | Unknown                            | I; GP        | I; H                                         |
| Portugal       | 2                   | Inactivated subunit; inactivated    | R; I; GP     | I; H                                         |
| Romania        | 3                   | Inactivated subunit                | I; GP        | I; H                                         |
| Spain          | 2                   | Inactivated subunit; inactivated    | R; I; GP     | I; H                                         |

GP: general practitioner/primary care database; H: hospital database/medical charts; I: interview with patient; I-MOVE+: Integrated Monitoring of Vaccines in Europe plus; P: pharmacist; R: register

### Table 1

Vaccine types used and source of information for vaccination status by study site, I-MOVE+ study, Europe, influenza season, 2015/16
### Table 2
Characteristics of influenza A(H1N1)pdm09 and influenza B hospitalised cases and corresponding test-negative controls included in the I-MOVE+ study, Europe, influenza season 2015/16

|                      | Influenza A(H1N1)pdm09 | Influenza B |
|----------------------|------------------------|-------------|
|                      | Cases (n = 355)        | Controls (n = 976) | Cases (n = 110) | Controls (n = 1,015) |
| **Median age in years (range)** | 76 (65–95) | 78 (65–101) | 76 (65–94) | 78 (65–101) |
| Aged 65–79 years     | 235/355 66.2%        | 535/976 54.8% | 76/110 69.1% | 566/1,015 55.8% |
| Sex = male           | 194/351 55.3%        | 512/975 52.5% | 57/110 51.8% | 520/1,014 51.3% |
| **2015/16 seasonal influenza vaccination** | 138/355 38.9% | 543/976 55.6% | 50/110 45.5% | 588/1,015 57.9% |
| **2014/15 seasonal influenza vaccination** | 136/347 39.2% | 537/958 56.1% | 57/109 51.8% | 586/998 59.0% |
| **Type of vaccine**  |                        |              |              |                      |
| Not vaccinated       | 217/353 61.5%        | 433/970 44.6% | 60/110 54.5% | 427/1012 42.2% |
| Inactivated subunit  | 77/353 21.8%         | 209/970 21.5% | 20/110 18.2% | 207/1012 20.5% |
| Inactivated split virion | 59/353 16.7% | 312/970 32.2% | 30/110 27.3% | 332/1012 32.8% |
| Adjuvanted           | 0/353 0.0%           | 16/970 1.6% | 0/110 0.0% | 46/1012 4.5% |
| **Underlying conditions** |                              |              |              |                      |
| Diabetes             | 99/347 28.5%         | 277/954 29.0% | 31/104 29.8% | 284/992 28.6% |
| Heart disease        | 215/351 61.3%        | 590/967 61.0% | 63/107 58.9% | 631/1006 62.7% |
| Lung disease         | 141/351 40.2%        | 438/965 45.4% | 46/108 42.6% | 484/996 48.6% |
| Immunodeficiency     | 7/343 2.0%           | 34/942 3.6% | 10/106 9.4% | 32/986 3.2% |
| Cancer               | 93/350 26.6%         | 263/963 27.3% | 19/105 18.1% | 280/1001 28.0% |
| Nutritional deficiency | 16/239 6.7%      | 65/723 9.0% | 9/84 10.7% | 83/757 11.0% |
| Renal disease        | 54/349 15.5%         | 221/960 23.0% | 20/106 18.9% | 236/996 23.7% |
| Dementia or stroke   | 46/346 13.3%         | 160/956 16.7% | 17/104 16.3% | 156/991 15.7% |
| Rheumatologic disease | 15/246 6.1%     | 80/737 10.9% | 11/87 12.6% | 83/757 11.0% |
| Obesityb             | 43/349 12.3%         | 139/951 14.6% | 5/104 4.8% | 123/985 12.5% |
| Any underlying condition | 325/350 92.9% | 908/976 93.0% | 99/100 99.0% | 955/1015 94.1% |
| ≥ 2 underlying conditions | 244/347 70.3% | 719/964 74.6% | 72/108 66.7% | 752/1006 74.8% |
| Functional impairmentc | 116/347 33.4%   | 347/948 36.6% | 20/109 18.3% | 359/988 36.3% |
| Hospitalisation in past 12 months | 152/345 44.1% | 446/960 46.5% | 39/108 36.1% | 475/989 48.0% |
| Current smoking      | 79/340 23.2%         | 183/901 20.3% | 36/102 35.3% | 210/927 22.7% |

| **Study sites** |                      |              |              |                      |
| Croatia           | 16/355 4.5% | 15/976 1.5% | 5/110 4.5% | 3/1,015 0.3% |
| Finland           | 18/355 5.1% | 57/976 5.8% | 3/110 2.7% | 35/1,015 3.4% |
| France            | 11/355 3.1% | 124/976 12.7% | 26/110 23.6% | 124/1,015 12.2% |
| Hungary           | 0/355 0.0% | 0/976 0.0% | 1/110 0.9% | 5/1,015 0.5% |
| Italy             | 3/355 0.8% | 102/976 10.5% | 10/110 9.1% | 249/1,015 24.5% |
| Lithuania         | 17/355 4.8% | 41/976 4.2% | 3/110 2.7% | 31/1,015 3.1% |
| Navarra           | 87/355 24.5% | 240/976 24.6% | 27/110 24.5% | 230/1,015 22.7% |
| The Netherlands   | 5/355 1.4% | 12/976 1.2% | 3/110 2.7% | 6/1,015 0.6% |
| Poland            | 17/355 4.8% | 14/976 1.4% | 6/110 5.5% | 9/1,015 0.9% |
| Portugal          | 14/355 3.9% | 35/976 3.6% | 1/110 0.9% | 1/1,015 0.1% |
| Romania           | 58/355 16.3% | 101/976 10.3% | 2/110 1.8% | 70/1,015 6.9% |
| Spain             | 109/355 30.7% | 235/976 24.1% | 23/110 20.9% | 252/1,015 24.8% |

| **Potential for misclassification** |                      |              |              |                      |
| Antivirals before swabbing | 36/353 10.2% | 32/972 3.3% | 7/107 7.5% | 27/1,012 2.7% |
| Swabbing within 3 days of onset | 216/355 60.8% | 518/976 53.1% | 54/110 49.1% | 585/1,015 57.6% |

1 MOVE+: Integrated Monitoring of Vaccines in Europe plus.

2 Indicates a significant difference (p value < 0.05) between cases and controls.

3 Defined as body-mass index ≥ 30 kg/m2.

4 Defined as Barthel score < 100 [22].
countries with at least one patient vaccinated with a specific type.

We also computed a pooled IVE with a two-stage model, adjusting study site-specific IVE for study site-specific confounders (same as listed above) when sample size allowed. We quantified the heterogeneity between site estimates using the I-square [23].

To minimise the inclusion of false influenza-negatives in the control group, we carried out sensitivity analyses by restricting population to (i) patients swabbed up to three days after symptom onset and (ii) patients not treated with antivirals until the day before swabbing.

### Results

A total of 2,077 patients meeting the inclusion criteria were recruited in the study. We excluded 472 controls (23%) recruited outside of the study period and 65 patients (4%) with missing information on vaccination status. We included 1,274 controls and 528 cases, of which 353 (67%) were influenza A(H1N1)pdm09 positive, 105 (20%) were influenza B-positive, 41 (8%) were influenza A(H3N2)-positive, 24 (5%) were influenza A (non-subtyped)-positive, two (<1%) were co-infected by influenza A(H1N1)pdm09 and B, one (<1%) was co-infected by influenza A(H3N2) and B and two (<1%) were co-infected by influenza A (non-subtyped) and B. Of the 52 cases of influenza B with a known lineage, 47

---

| Analyses                                           | Model used for adjustment | Vaccinated /cases | Vaccinated /controls | Adjusted IVE | 95% CI          |
|----------------------------------------------------|---------------------------|-------------------|---------------------|--------------|-----------------|
| **Overall**                                        |                           |                   |                     |              |                 |
| Initial                                            | 138/355                   | 543/976           | 42.4                | 22.0 to 57.4 |
| Full                                               | 131/336                   | 509/923           | 39.4                | 16.6 to 55.9 |
| **By risk groups**                                 |                           |                   |                     |              |                 |
| At least one underlying condition                  |                           |                   |                     |              |                 |
| Initial                                            | 130/317                   | 499/892           | 35.7                | 11.4 to 53.3 |
| Initial plus severity                              |                           |                   | 35.6                | 11.2 to 53.3 |
| Diabetes mellitus                                  |                           |                   |                     |              |                 |
| No                                                 |                           |                   |                     |              |                 |
| Initial                                            | 98/242                    | 370/674           | 33.9                | 4.6 to 54.2  |
| Yes                                                |                           |                   |                     |              |                 |
| Initial                                            | 33/96                     | 150/266           | 58.5                | 22.8 to 77.7 |
| Initial plus severity                              |                           |                   | 58.5                | 22.7 to 77.8 |
| Heart disease                                      |                           |                   |                     |              |                 |
| No                                                 |                           |                   |                     |              |                 |
| Initial                                            | 54/131                    | 207/372           | 37.3                | -1.2 to 61.1 |
| Yes                                                |                           |                   |                     |              |                 |
| Initial                                            | 80/211                    | 321/581           | 38.4                | 6.5 to 59.5  |
| Initial plus severity                              |                           |                   | 39.0                | 7.3 to 59.9  |
| Lung disease                                       |                           |                   |                     |              |                 |
| No                                                 |                           |                   |                     |              |                 |
| Initial                                            | 61/203                    | 250/515           | 39.7                | 8.0 to 60.4  |
| Yes                                                |                           |                   |                     |              |                 |
| Initial                                            | 72/139                    | 276/434           | 42.4                | 7.2 to 64.3  |
| Initial plus severity                              |                           |                   | 42.8                | 7.8 to 64.5  |
| Cancer                                             |                           |                   |                     |              |                 |
| No                                                 |                           |                   |                     |              |                 |
| Initial                                            | 93/252                    | 375/691           | 35.7                | 6.7 to 55.7  |
| Yes                                                |                           |                   |                     |              |                 |
| Initial                                            | 41/90                     | 150/256           | 47.7                | 4.8 to 71.3  |
| Initial plus severity                              |                           |                   | 47.8                | 4.8 to 71.4  |
| Vaccine type                                       |                           |                   |                     |              |                 |
| Inactivated subunit                                |                           |                   |                     |              |                 |
| Initial                                            | 77/224                    | 209/538           | 28.1                | -8.6 to 52.4 |
| Inactivated split virion                           |                           |                   |                     |              |                 |
| Initial                                            | 59/178                    | 312/588           | 54.7                | 30.7 to 70.4 |
| Sensitivity analyses                               |                           |                   |                     |              |                 |
| Two-stage model                                    |                           |                   |                     |              |                 |
| Two-stage                                          | 132/329                   | 527/932           | 49.0                | 13.5 to 70.0 |
| Restricted to patients swabbed within 3 days       |                           |                   |                     |              |                 |
| Initial                                            | 85/216                    | 313/518           | 49.1                | 23.8 to 66.0 |
| Restricted to patients not receiving antivirals before swabbing |   |                   |                     |              |                 |
| Initial                                            | 126/317                   | 531/940           | 42.2                | 20.8 to 57.8 |

CI: confidence interval; I MOVE+: Integrated Monitoring of Vaccines in Europe plus; IVE: influenza vaccine effectiveness.

* Initial: one-stage model adjusted for study site, date of symptom onset and age (modelled as restricted cubic splines). Full: one-stage model adjusted for study site, date of symptom onset, age (modelled as restricted cubic splines), lung, heart, renal disease, diabetes mellitus, cancer, obesity (body-mass index ≥ 30 kg/m²) and hospitalisation for underlying conditions in past year. Severity: hospitalisations for underlying conditions in the previous year.

* Poland and Hungary were excluded because there were no vaccinated controls in Poland and no cases in Hungary.
(90%) were Victoria and 5 (10%) were Yamagata. The 42 cases positive for influenza A(H3N2) did not allow us to compute IVE against this subtype.

The maximum number of influenza A(H1N1)pdm09 cases were recruited in weeks 5 to 8 of 2016 and the maximum number of influenza B and A(H3N2) cases in week 10 (Figure 2).

Overall, 216/528 cases (41%) and 694/1,274 controls (54%) had received trivalent inactivated vaccines. Among those vaccinated, 51 (6%) received adjuvanted vaccines, 338 (37%) inactivated subunit vaccines, 513 (56%) inactivated split virion vaccines and the information on vaccine type was missing for 8 (1%) vaccinated patients. Age and time adjusted IVE against any influenza was 39% (95% confidence interval (CI): 22 to 53).

Vaccine effectiveness against hospitalised influenza A(H1N1)pdm09

We included in this analysis 355 cases of influenza A(H1N1)pdm09, of whom 138 (39%) were vaccinated, and 976 controls, of whom 543 (56%) vaccinated. The median age of A(H1N1)pdm09 cases and controls was 76 (interquartile range (IQR) = 12 years) and 78 (IQR = 12 years) years respectively (p = 0.001). The proportion of patients with underlying conditions was similar among cases and controls except for renal (16% among cases vs 23% among controls, p = 0.003) and rheumatologic diseases (6% among cases vs 11% among controls, p = 0.033). Ten percent of A(H1N1)pdm09 cases and 3% of controls had received antivirals before swabbing (p < 0.001) and 61% of cases vs 53% of controls were swabbed within 3 days after symptoms onset (p = 0.013) (Table 2).

One-stage pooled IVE against A(H1N1)pdm09 adjusted for onset time and age was 42% (95% CI: 22 to 57) and 39% (95% CI: 17 to 56) when further adjusted for a range of underlying conditions and hospitalisation in the previous year (Table 3). IVE against A(H1N1)pdm09 was 59% (95% CI: 23 to 78), 48% (95% CI: 5 to 71), 43% (95% CI: 8 to 65) and 39% (95% CI: 7 to 60) in patients with diabetes mellitus (n = 362), cancer (n = 346), lung (n = 573) and heart disease (n = 792), respectively (Table 3).

IVE against A(H1N1)pdm09 was 28% (95% CI: −9 to 52) for inactivated subunit vaccines (n = 762) and 55% (95% CI: 31 to 70) for inactivated split virion vaccines (n = 716).
Table 5
Pooled adjusted seasonal vaccine effectiveness against hospitalised influenza B among elderly people overall and by risk groups, I-MOVE+ study, Europe, influenza season 2015/16

| Model used for adjustment | Vaccinated /cases | Vaccinated /controls | Adjusted IVE | 95% CI |
|---------------------------|-------------------|----------------------|-------------|-------|
| Overall                   |                   |                      |             |       |
| Overall                   | Initial           | 50/110               | 588/1,015   | 51.8  | 23.7 to 69.5 |
| Overall                   | Full              | 46/101               | 544/948     | 47.0  | 13.1 to 67.7 |
| By risk groups            |                   |                      |             |       |
| At least one underlying condition | Initial | 47/97               | 536/929     | 50.2  | 18.7 to 69.4 |
|                          | Initial plus severity |            |             | 49.4  | 17.5 to 69.0 |
| Diabetes mellitus         |                   |                      |             |       |
| No                       | Initial           | 33/72                | 404/696     | 40.9  | −7.1 to 67.4  |
|                          | Initial plus severity |            |             | 62.1  | 5.8 to 84.7   |
|                          |                   |                      |             |       |
| Heart disease             |                   |                      |             |       |
| No                       | Initial           | 16/44                | 211/368     | 66.5  | 27.6 to 84.5  |
|                          | Initial plus severity |            |             | 36.3  | −22.2 to 66.8 |
|                          |                   |                      |             |       |
| Lung disease              |                   |                      |             |       |
| No                       | Initial           | 27/61                | 258/502     | 32.8  | −28.6 to 64.8 |
|                          | Initial plus severity |            |             | 60.5  | 19.2 to 80.6  |
|                          |                   |                      |             |       |
| Vaccine type              |                   |                      |             |       |
| Inactivated subunit       | Initial           | 20/61                | 207/542     | 49.0  | 13.5 to 70.0  |
|                          | Initial plus severity |            |             | 59.9  | 18.2 to 74.0  |
| Inactivated split virion  | Initial           | 30/74                | 332/652     | 54.1  | 18.9 to 74.0  |

| Sensitivity analyses      |                   |                      |             |       |
| two-stage model           |                   |                      |             |       |
| Restricted to patients swabbed within 3 days | Initial | 31/54                | 358/585     | 25.0  | −50.5 to 62.6 |
|                          | Initial plus severity |            |             | 52.3  | 22.8 to 70.5  |

CI: confidence interval; I MOVE+: Integrated Monitoring of Vaccines in Europe plus; IVE: influenza vaccine effectiveness.

a Initial: one-stage model adjusted for study site, date of onset and age (modelled as restricted cubic splines). Full: one-stage model adjusted for study site, date of symptom onset, age (modelled as restricted cubic splines), lung, heart, renal disease, diabetes mellitus, cancer, obesity and hospitalisation in the previous year. Severity: hospitalisations for underlying conditions in the previous year.

b Croatia, Hungary, Italy, Lithuania, the Netherlands, Poland, Portugal and Romania were excluded from the two-stage analyses because there were no vaccinated controls and/or cases, respectively.

swabbed within 3 days of symptoms onset (n=734) (Table 3).

**Vaccine effectiveness against hospitalised influenza B**

We included in this analysis 110 cases of influenza B, of whom 50 (46%) were vaccinated and 1,015 controls, of whom 588 (58%) vaccinated. The median age of cases and controls were 76 (IQR: 12 years) and 78 years (IQR: 12 years) respectively (p = 0.056). A lower proportion of cases than controls had cancer (19% vs 28%, p = 0.037), a functional impairment (18% vs 36%, p < 0.001), and had been hospitalised in the previous 12 months (36% vs 48%, p = 0.02). The proportion of current smokers was higher among influenza B cases than among controls (35% vs 23%, p = 0.007) (Table 2).

One stage pooled IVE against influenza B adjusted for symptom onset time and age was 52% (95% CI: 24 to 70) and 47% (95% CI: 13 to 68) when further adjusted for a range of underlying conditions and hospitalisation in the previous year (Table 5). IVE was 62% (95% CI: 5 to 85), 60% (95% CI: 18 to 80) and 36% (95% CI: 23 to 67) in patients with diabetes mellitus (n = 302), lung (n = 520) and heart disease (n = 675), respectively.

IVE against influenza B was 49% (95% CI: 14 to 70) for inactivated subunit vaccines (n = 603) and 54% (95% CI: 19 to 74) for inactivated split virion vaccines (n = 726).

Study site specific IVE ranged between 18% (95% CI: −106 to 67) in Finland (n = 38) and 76% (95% CI: −24 to 95) in Italy (n = 259) (Table 6). There was no statistical heterogeneity between study site specific IVE.
estimates (I2 = 0%). The two-stage pooled analysis (n = 944) included Finland, France, Italy, Navarre and Spain. IVE was 47% (95% CI: 11.9 to 68.2) – 47.0 – 11.9 to 68.2 – 0.0%.

### Table 6

| Study site | Inclusion period | Variables used for adjustment | Vaccinated /cases | Vaccinated /controls | Adjusted IVE | 95% CI | I-square |
|------------|------------------|-------------------------------|-------------------|----------------------|--------------|--------|----------|
| Finland    | 2016w8–2016w15   | Date                          | 2/3               | 22/35                | 23.3         | -1,785.9 to 96.9 – |
| France     | 2016w4–2016w14   | Date, age, functional impairment | 17/26             | 87/120               | 18.1         | -105.6 to 67.4 – |
| Italy      | 2016w1–2016w12   | Date                          | 2/10              | 121/249              | 75.5         | -23.7 to 95.1 – |
| Navarre    | 2015w53–2016w17  | Date                          | 17/27             | 165/230              | 59.4         | -2.5 to 83.9 – |
| Spain      | 2016w2–2016w16   | Date, lung disease, dependency | 11/20             | 159/220              | 44.3         | -48.9 to 79.1 – |
| two-stage pooled (n = 944) | – | – | – | – | 47.0 | 11.9 to 68.2 – |

CI: confidence interval; I MOVE+: Integrated Monitoring of Vaccines in Europe plus; IVE: influenza vaccine effectiveness; w: week (International Organisation for Standardisation (ISO) week).

Croatia, Hungary, Italy, Lithuania, the Netherlands, Poland, Portugal and Romania were excluded from the two-stage analyses because there were no vaccinated controls and/or cases.

Date of onset and age modelled as restricted cubic spline with four knots.

Discussion

Our results suggest that the seasonal IVE against hospitalised influenza among elderly people was moderate during the 2015/16 influenza season in Europe for influenza: 39% overall, 42% against influenza A(H1N1)pdm09 and 52% against influenza B. These estimates did not vary between categories of underlying conditions.

Data from European virological surveillance reported that most of the characterised influenza A(H1N1)pdm09 viruses belonged to the emerging subclade 6B.1, defined by haemagglutinin amino acid substitutions S162N and I216T [18]. Despite these genetic evolutions, A(H1N1)pdm09 viruses were considered antigenically similar to the northern hemisphere vaccine component A/California/7/2009. IVE estimates against hospitalised A(H1N1)pdm09 was consistent with the results we reported in 2012/13 and 2013/14 among hospitalised elderly people [24,25].

In 2015/16, the circulating influenza B Victoria lineage was distinct from the Yamagata vaccine component [26] and there was no quadrivalent vaccine used in our study population. IVE against influenza B was close to what we reported, using the same generic protocol, in 2012/13 (66% in the 65–79 year-olds and 44% in the 80 year-olds and older) in a season with co-circulation of B Victoria and Yamagata lineages and a Yamagata vaccine component [24,27]. These results suggest some cross-lineage protection and they are in line with previously reported data in GP-based studies [28,29] and a meta-analysis of eight randomised controlled trials with mismatched B viruses resulting in a VE of 52% (95% CI: 19 to 72) among healthy adults [30]. Further studies are needed to increase the understanding of mechanisms of cross-lineage protection for influenza B and better guide policy makers in terms of recommendations for using trivalent or tetravalent seasonal vaccines.

We observed higher point estimates of IVE for the inactivated split virion vaccines compared with inactivated subunit vaccines, although the 95% CIs of the point estimates were widely overlapping. The completeness of data on vaccine type was high (1% of missing vaccine type among those vaccinated), thus these results, concurring with published data [31-33], could be due to differences in T-cell responses conferred by the two vaccine types [34]. However, they should be interpreted with caution as they may be due to random variation. Further evidence, and pooling of several years of data would be required to obtain precise vaccine type specific effectiveness. Higher adjuvant vaccine coverage would be needed to compute adjuvant vaccine specific IVE. This would be useful information to adapt influenza vaccination strategies among elderly people.

Recent reviews underlined the need for further evidence of seasonal IVE against laboratory-confirmed influenza in elderly people and patients with underlying conditions [8-13]. We were able to collect high quality data from 1,802 elderly patients hospitalised with SARI, making our study one of the largest hospital-based studies on IVE. The large number of participants,
and a vaccine coverage close to 50%, enabled us to compute IVE against type/subtype-specific influenza among patients with specific underlying conditions. Our results suggest that, in 2015/16, the seasonal influenza vaccine provided protection against hospitalised influenza A(H1N1)pdm09 and B in the elderly with diabetes mellitus, heart, and lung disease. We were unable to refine the underlying conditions categories further. To better guide vaccine recommendations, IVE among patients receiving specific treatment (e.g. statins [35,36], chemotherapy [9,37]) or with more specific conditions (e.g. asthma, chronic obstructive pulmonary disease) would be needed. A larger sample size would be required for such studies.

We collected information related to access to care, health conditions and smoking status. Recruited cases and controls were similar. We adjusted our estimates for study site, onset week and age. Further adjustment for potential confounders (underlying lung, heart, renal disease, diabetes mellitus, cancer, obesity and hospitalisations in the past year) did not change the estimates. However, as in any observational study, we cannot exclude unmeasured confounding leading to over- or under-estimation of the IVE.

The contribution to the pooled dataset was different between study sites. The two Spanish sites recruited 44% of the patients. The viruses circulating and vaccines used in Spain were similar to the other countries. Consequently we do not expect the over-representation of Spanish sites to have biased our overall estimates. Variations in the number of recruited individuals may be explained by differences in local influenza activity or number and size of participating hospitals/services. We believe that access to hospitalisation in case of severe influenza is similar across participating European countries. A common generic protocol and the monitoring of its implementation through on-site visits contributed to ensuring comparability of patients recruited and data collected across study sites. We measured low statistical heterogeneity based on I-square values. However, small number of estimates and large study-specific CIs may hinder adequate qualitative assessment of heterogeneity between studies [38]. True differences between study site specific IVE could be related to different vaccines used during this season or different immunological profiles of recruited patients including their past vaccination histories [39]. Larger study site-specific sample sizes are required to ensure that the differences in IVE across study sites are not due to chance. Currently, multicentre studies are necessary to obtain precise IVE estimates.

A recent publication by Foppa et al. suggested that measuring IVE against laboratory-confirmed influenza SARI hospitalisation using the TND was subject to biases if the test-negative controls were hospitalised because of an exacerbation of underlying lung disease unrelated to a respiratory infection [40]. In our study, cases and controls had similar prevalence of underlying lung disease. Underlying lung disease did not appear to confound IVE estimates, even when combined with a proxy of its severity (hospitalisation because of underlying conditions in the past 12 months). Cohort and TND-based IVE estimates against laboratory-confirmed hospitalised influenza in Navarre repeatedly showed similar estimates, reassuring on the appropriateness of TND at hospital level [41].

Several studies suggest that past influenza vaccinations may decrease or enhance current vaccine effectiveness depending on previous and current vaccine and circulating strains as well as past exposure to the virus [24,32,42-44]. A large proportion of our vaccinated population had been vaccinated in the previous season(s) but the very small number of patients with varying repeated vaccination status over the years did not allow us to measure the effect of previous vaccinations. To understand the effect of repeated vaccinations on IVE, large cohorts of individuals with different vaccination patterns and symptomatic (and asymptomatic) influenza infection status over the years would be needed.

**Conclusion**

Our multicentre test-negative case–control study estimated that in 2015/16 the seasonal influenza vaccination prevented approximately half of the cases of hospitalisation with laboratory-confirmed influenza among vaccinated elderly people. Our results suggest that vaccination provided similar protection to elderly patients with underlying diabetes mellitus, cancer, lung and heart diseases. Because vaccination remains the most effective preventive measure against severe influenza among elderly people, increasing the vaccine coverage in this group should be a priority. This pilot season of the hospital-based I-MOVE + project proved that obtaining precise estimates of IVE against a severe influenza outcome among elderly people was feasible. Enlarging our network and its sample size will enable us to better guide vaccination strategies against severe influenza cases by comparing the performance of different vaccine types and identifying risk groups for poor response to vaccination.

**I-MOVE + hospital working group**

EpiConcept: Alain Moren

Spain: Jone M. Altzibar, Ion García Arraras (Subdirección de Salud Pública de Gipuzkoa, CIBERESP, Basque Country, Spain), Gustavo Cilla (Donostia University Hospital, CIBERES, San Sebastian, Basque Country, Spain), Elisa Marco (Dirección General de Salud Pública, Aragón, Spain), Matxalen Vidal, Manuel Omeñaca (Miguel Servet University Hospital, Zaragoza, Spain)

Navarra: J. Castilla (Instituto de Salud Pública de Navarra, IdiSNIA, CIBERESP, Pamplona), A Navascués, C Ezepeleta (Complejo Hospitalario de Navarra, IdiSNIA, Pamplona, Spain), L Barrado (Hospital de Estella, Spain), MT Ortega (Hospital de Tudela, Spain)
Italy: A. Bella, M.R. Castrucci, S. Puzelli (Istituto Superiore di Sanità, Rome), M.Chironna, C. Germinario (Polyclinico Hospital, University of Bari); F. Ansaldi, A. Orsi (IRCCS AOU San Martino- IST, Genoa hospital); I. Manini, E. Montomoli (Department of Molecular and Developmental Medicine, University of Siena)

Romania: E. Lupulescu, M. Lazar, CM Cherciu, C. Tecu, ME Mihai (National Institute of Research Cantacuzino), M. Nitescu (INBI Matei Bals, Bucharest), D. Leca (UMF Gr. Popa Iasi), E. Ceausu (UMF Carol Davila Bucharest, Infectious Diseases Hospital V. Babes, Bucharest)

France: N. Lenz, Z. Lesieur (Innovative clinical research network in vaccination (I-REIVAC), P. Louergue (Inserm, CIC Cochin-Pasteur, I-REIVAC, Paris), V. Fouloungne, F. Letoi, C. Merle (CHU de Montpellier, I-REIVAC), P. Vanhems (Hôpital Edouard Herriot, Lyon, I-REIVAC), B. Lina (Université Lyon 1, Centre National de Référence virus influenza France Sud, Lyon, France)

Finland: H. Nohynek, A. Haveri (National Institute for Health and Welfare)

Lithuania: M. Kuliese, D. Velyvyte (Department of Infectious Diseases of Lithuanian University of Health Sciences, Kaunas, Lithuania), R. Grimalauskaite, G. Damuleviciene, V. Lesaulaite (Department of Geriatrics, Lithuanian University of Health Sciences, Kaunas, Lithuania), L. Jancoriene, B. Zablockiene, A. Ambrozañis (Clinic of Infectious, Chest Diseases, Dermatovenerology and Allergology, Vilnius University Faculty of Medicine, Vilnius, Lithuania)

Portugal: B. Nunes, A.P. Rodrigues (National Health Institute Doutor Ricardo Jorge, Lisbon), V. Gomes, R. Corte-Real (Centro Hospitalar de Lisboa Central, Lisbon), J. Poças, M.J. Peres (Centro Hospitalar de Setúbal, Setúbal)

Croatia: Adriana Vinc, Antea Topic, Neven Papić, Jenleva Budimir Mihalijevi, (all from the University Hospital for Infectious Diseases ‘Dr. Fran Mihaljević’, Zagreb), Iva Pem Novosel, Goranka Petrović, Martina Zajec, Vladimir Draženović (all from the University Hospital for Infectious Diseases ‘Dr. Fran Mihaljević’, Zagreb), Iva Pem Novosel, Goranka Petrović, Martina Zajec, Vladimir Draženović (all from the Croatian Institute of Public Health, Zagreb)

Hungary: Éva Hercegh, Bálint Szalai (Influenza Virus Laboratory, National Center for Epidemiology, Budapest, Hungary), Katalin Antmann (Hospital Hygiene Department, Semmelweis University, Budapest, Hungary), Kamilla Nagy, (Hospital Hygiene Department, University of Szeged, Szeged, Hungary)

Acknowledgements

The I-MOVE+ project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 634446.

The Lithuanian I-MOVE+ study sites were supported by a grant from the Research Council of Lithuania (SEN-03/2015). We are grateful to all patients, medical staff, study nurses and epidemiologists from the 12 study sites who actively participated in the study.

EpiConcept: Esther Kissling

Italy: Anna Pina Palmieri, Stefania Giannitelli and Alessia Ranghiàschi (Istituto Superiore di Sanità, Rome, Italy).

Romania: Rodica Bacruban, Delia Azamfire, Aura Dumitrescu, Elena Ianosik (INBI Matei Bals), Elena Duca, Codrina Bejan, Anda Teodor (Infectious Diseases Hospital Sf. Parascheva Iasi), Simin-Aysel Florescu, Corneliu Popescu, Gratiela Tardei, (UMF Carol Davila Bucharest, Infectious Diseases Hospital V. Babes, Bucharest, Romania)

France: Julien Charpentier, Nathalie Marin (Service de réanimation médicale, Cochin-Pasteur, APHP, Université Paris Descartes, Sorbonne Paris Cité, Paris, France), Benoît Doumenc (Service des urgences, Cochin-Pasteur, APHP, Université Paris Descartes, Sorbonne Paris Cité, Paris, France), Claire Le jeune (Service de médecine Interne, Cochin-Pasteur, APHP, Université Paris Descartes, Sorbonne Paris Cité, Paris, France), Anne Krivine (Service de virologie, Cochin-Pasteur, APHP, Université Paris Descartes, Sorbonne Paris Cité, Paris, France), Sonia Momčilović: CIC Cochin-Pasteur, APHP, Université Paris Descartes, Sorbonne Paris Cité, Paris, France, Thomas BENET (Infection Control and Epidemiology Unit, Hôpital Edouard Herriot, Lyon), Séllah AMOUR (Infection Control and Epidemiology Unit, Hôpital Edouard Herriot, Lyon), Laetitia HENAFF (Infection Control and Epidemiology Unit, Hôpital Edouard Herriot, Lyon).

Finland: Jukka Jokinen, Outi Lyytikäinen and Arto Pumulo (study design, protocol writing), Päivi Sirén (clinical data collection), Esa Ruokokoski (data management), The laboratory staff in Viral Infections Unit of THL, Tampere University Hospital, Hatanpää Hospital (collaboration with the clinical work and data collection).

Portugal: Baltazar Nunes, Ana Paula Rodrigues, Raquel Gulomar (Infectious Diseases Department, National Health Institute Doutor Ricardo Jorge, Lisbon, Portugal), Victor Gomes, Filipa Quaresma, Luis Vale, Teresa Garcia, Teresa Bernardo, Liliana Dias, Paula Fonseca, Helena Amorim, João Rolo, Helena Pacheco, Paula Branquinho, Rita Corte-Real (Centro Hospitalar de Lisboa Central, Lisbon, Portugal), José Poças, Paula Lopes, Maria João Peres, Rosa Ribeiro, Paula Duarte, Ermelinda Pedroso, Sara Rodrigues, Ana Rita Silva, Diana Gomes Pedreira, Marta Ferreira Fonseca, (Centro Hospitalar de Setúbal, Setúbal, Portugal).

Conflict of interest

None declared.

Authors’ contributions

Marc Rondy was involved in the original methodological design of the study (generic protocol). He coordinated the European hospital IVE network, undertook the statistical analysis on which the research article is based and led the writing of the research article.

Marta Valenciano initiated the original methodological design of the study. She coordinated the European hospital
References

1. Mertz D, Kim TH, Johnstone J, Lam P-P, Science M, Kuster SP, et al. Populations at risk for severe or complicated influenza illness: systematic review and meta-analysis. BMJ. 2013;347(aug23 1):f15681.

2. Hewitt R, Farne Ritchie A, Luke E, Johnstone SL, Mallia P. The role of viral infections in exacerbations of chronic obstructive pulmonary disease and asthma. Ther Adv Respir Dis. 2016;10(2):158-74. DOI: 10.1177/1753486915618131. PMID: 26619007.

3. Rothenberg MB, Haessler SD, Brown RB. Complications of influenza. Am J Med. 2008;121(12):1258-64. DOI: 10.1016/j.amjmed.2007.10.040. PMID: 1874680.

4. Kunisaki KM, Janoff EN. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis. 2009;9(9):493-504. DOI: 10.1016/S1473-3099(09)70175-6. PMID: 19608174.

5. Muller LM, Gorter KJ, Hak E, Goudwaard WL, Schellevis FG, Hoepelman AI, et al. Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. Clin Infect Dis. 2005;41(3):281-8. DOI: 10.1086/431587. PMID: 16007521.

6. Frasca D, Diaz A, Romero M, Mendez NV, Landin AM, Ryan JG, et al. Young and elderly patients with type 2 diabetes have optimal B cell responses to the seasonal influenza vaccine. Vaccine. 2013;31(33):3603-10. DOI: 10.1016/j.vaccine.2013.05.003. PMID: 23719314.

7. Muszkat M, Friedman G, Dannenberg HD, Greenbaum E, Lipo M, Heymann Y, et al. Response to influenza vaccination in community and nursing home residing elderly: relation to clinical factors. Exp Gerontol. 2003;38(11):1067-203. DOI: 10.1016/j.exger.2003.07.004. PMID: 14580873.

8. Jefferson T, Di Pietrantonj C, Al-Ansary LA, Ferroni E, Botella J. Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods. 2006;11(2):193-206. DOI: 10.1037/1082-989X.11.2.193. PMID: 16786338.

9. Roche C. I-MOVE+ Marginplus contribution and management. They read, contributed and approved the manuscript final version. IVE network and contributed to the writing of the research article.

10. Amapo Larrauri, Itziar Casado, Valeria Alofnsi, Daniela Pitigoi, Odile Launay, Riva S. Syrrañen, Giedre Genaflaita, Ausenda Machado, Vesna Višekruna Vučina, Judith Kristzsin Horváth, Iwona Paradowska-Stankiewicz, Sierk D. Marbus, Alina Gherasim, Jorge Alberto Díaz-González, Caterina Rizzo, Alina E. Iacovlinč, Florence Gallier, Nilima Ikenen, Aukse Mickiene, Veronica Gomez, Sanja Kurečić Filipović, Annamária Ferenczi, Monika R. Korcinska and Rianne van Galgeldonk-Lafeber were responsible for the coordination of the data collection and management. They were in charge of the data published in this research article. They read, contributed and approved the manuscript final version.

The I-MOVE+ hospital working group contributors contributed to developing the study site specific protocol. They were in charge of supervising the study at the hospital level and collect the data published in this research article. They read, contributed and approved the manuscript final version.

Journal of the European Union. Luxembourg: Publications Office of the European Union; 2009. http://eur-lex.europa.eu/legal-content/EN/TXT/html/?uri=CELEX:32009H1019&from=EN

15. Vaccines against influenza WHO position paper – November 2012. Wky Epidemiol Rec. 2012;87(4):261-76. PMID: 23210147.

16. European Centre for Disease Prevention and Control (ECDC). Seasonal influenza vaccination in Europe - Overview of vaccination recommendations and cover rates among the EU Member States for the 2012-13 influenza season. Stockholm: ECDC; Jan 2015. Available from: http://ecdc.europa.eu/en/publications/Publications/seasonal-influenza-vaccination-Europe-2012-13.pdf.

17. World Health Organization (WHO). Recommended composition of influenza virus vaccines for use in the 2015-2016 northern hemisphere influenza season. Geneva: WHO; Feb 2015. Available from: http://www.who.int/entity/influenza/vaccines/virus/recommendations/2015_16_north/en/index.html.

18. European Centre for Disease Prevention and Control (ECDC). Influenza vaccine characterisation. Summary Europe. Stockholm: ECDC; Jun 2016. Available from: http://ecdc.europa.eu/en/publications/Publications/influenza-virus-characterisation-june-2016.pdf.

19. EpiConcept. Protocol for hospital-based test negative control studies to measure seasonal influenza vaccine effectiveness against influenza laboratory confirmed SARI hospitalisation among the elderly across the European Union and European Economic Area Member States. Paris: Integrated Monitoring of Vaccines in Europe plus (I-MOVE+). [Accessed 4 May 2016]. Available from: https://drive.google.com/a/epiconcept.fr/file/d/0B54XpZN4SY65QXFqQThQNEQ5cmM/view.

20. EpiConcept. I-MOVE+ (Integrated Monitoring of Vaccines in Europe plus). Paris: I-MOVE+. [Accessed 5 Jul 2017]. http://www.i-moveplus.eu/wp2.

21. VENICE II Consortium. Seasonal influenza vaccination survey in EU/EEA, influenza season 2009-10. Final report. Rome: VENICE project; 2011. [Accessed 22 Oct 2013]. Available from: http://venice.cineca.org/Final_Scenal_Influenza_Vaccination_Survey_2010.pdf.

22. Mahoney FI, Barthel DW. Functional evaluation: the Barthel Index. MD State Med J. 1965;61(5):245-950.

23. Huedo-Medina TB, Sánchez-Meca J, Martín-Martínez F, Botella J. Predominance of influenza A(H1N1)pdm09 virus genetic subclade 6B.1 and influenza B/Victoria lineage viruses in the south hemisphere influenza season. Euro Surveill. 2016;21(13):30184. DOI: 10.2807/1560-7917.ES2015.20.2.21011. PMID: 25613779.

24. Rondy M, Launay O, Puig-Barberà J, Gemenaitė G, Castilla J, de Gaetano Donati, K. et al. 2012/13 influenza vaccine effectiveness against hospitalised influenza A(H3N2)pdm09, A(H1N1) and B: estimates from a European network of hospitals. Euro Surveill. 2015;20(2):21011. DOI: 10.2807/1560-7917.ES2015.20.2.21011. PMID: 25613779.

25. Rondy M, Castilla J, Launay O, Costanzo S, Ezpeleta C, Galtier F, et al. Moderate influenza vaccine effectiveness against hospitalised A(H1N1)pdm09, A(H3N2) and B: results from the InNHOVE network. Hum Vaccin Immunother. 2016;12(5):1217-24. DOI: 10.1080/21645515.2015.1126013. PMID: 27065000.

26. Broberg E, Melidou A, Prosek M, Brajkstad K, Hungrøe O. Predominance of influenza A(H1N1)pdm09 virus genetic subtype 6B.1 and influenza B/Victoria lineage viruses at the start of the 2015/16 influenza season in Europe. Euro Surveill. 2016;21(31):30184. DOI: 10.2807/1560-7917.ES.2016.21.31.30184. PMID: 27074657.

27. European Centre for Disease Prevention and Control (ECDC). Influenza virus characterisation Summary Europe. Stockholm: ECDC; Jul 2013. Available from: http://ecdc.europa.eu/en/publications/Publications/influenza-virus-characterisation-july-2013.pdf.

28. Skowronski DM, Janiau NZ, De Serres G, Sabaudic S, Eshaghii A, Dickinson JA, et al. Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses. PLoS One. 2014;9(9):e92953. DOI: 10.1371/journal.pone.0092153. PMID: 24667168.

29. Skowronski DM, Janiau NZ, Sabaudic S, De Serres G, Winter A-L, Gubbay JB, et al. Influenza A/subtype and B/lineage effectiveness estimates for the 2011-12 influenza season: cross-season and cross-lineage protection with unchanged vaccine. J Infect Dis. 2014;210(1):126-37. DOI: 10.1093/infdis/jiu048. PMID: 2446529.

30. Visca PM, Chit A, De Gubbay C, Hallett D, Meier G, Chen MH, et al. Comparing influenza vaccine efficacy against mismatched and matched strains: a systematic review and meta-analysis. BMJ. 2015;311(7513):153. DOI: 10.1136/bmj.04950265.
31. Talbot HK, Nian H, Zhu Y, Chen Q, Williams JV, Griffin MR. Clinical effectiveness of split-virion versus subunit trivalent influenza vaccines in older adults. Clin Infect Dis. 2015;60(8):1170-5. DOI: 10.1093/cid/civ019 PMID: 25697739

32. Castilla J, Navascués A, Fernández-Alonso M, Reina G, Pozo F, Casado I, et al. Effectiveness of subunit influenza vaccination in the 2014-2015 season and residual effect of split vaccination in previous seasons. Vaccine. 2016;34(1):1350-7. DOI: 10.1016/j.vaccine.2016.01.054 PMID: 26854911

33. Puig-Barberà J, García-de-Lomas J, Diez-Domingo J, Arnedo-Pena A, Ruiz-Garcia M, Limón-Ramirez R, et al. Influenza vaccine effectiveness in preventing influenza A(H3N2)-related hospitalizations in adults targeted for vaccination by type of vaccine: a hospital-based test-negative study, 2011-2012 A(H3N2) predominant influenza season, Valencia, Spain. PLoS One. 2016;11(1):e0112294. DOI: 10.1371/journal.pone.0112294 PMID: 25392931

34. Co MDT, Orphin L, Cruz J, Pazoles P, Green KM, Potts J, et al. In vitro evidence that commercial influenza vaccines are not similar in their ability to activate human T cell responses. Vaccine. 2009;27(2):319-27. DOI: 10.1016/j.vaccine.2008.09.092 PMID: 18977404

35. Atmar RL, Keitel WA. Influenza Vaccination of Patients Receiving Statins: Where Do We Go From Here? J Infect Dis. 2016;213(8):1211-3. DOI: 10.1093/infdis/jiv459 PMID: 26516140

36. Black S, Nicolay U, Del Giudice G, Rappuoli R. Influence of Statins on Influenza Vaccine Response in Elderly Individuals. J Infect Dis. 2016;213(8):1224-8. DOI: 10.1093/infdis/jiv56 PMID: 26516142

37. Choi DK, Fuleihan RL, Walterhouse DO. Serologic response and clinical efficacy of influenza vaccination in children and young adults on chemotherapy for cancer. Pediatr Blood Cancer. 2016;63(1):2011-8. DOI: 10.1002/pbc.26110 PMID: 27327360

38. Rücker G, Schwarzer G, Carpenter JR, Schumacher M. Undue reliance on I(2) in assessing heterogeneity may mislead. BMC Med Res Methodol. 2008;8(1):79. DOI: 10.1186/1471-2288-8-79 PMID: 19056727

39. Skowronski DM, Chambers C, Sabaiduc S, Janua NZ, Li G, Petric M, et al. Pre- and postpandemic estimates of 2009 pandemic influenza A(H1N1) seroprotection to inform surveillance-based incidence, by age, during the 2013-2014 epidemic in Canada. J Infect Dis. 2015;211(1):109-14. DOI: 10.1093/infdis/jiu366 PMID: 24973459

40. Foppa IM, Ferdinands JM, Chaves SS, Haber MJ, Reynolds SB, Flannery B, et al. The case test-negative design for studies of the effectiveness of influenza vaccine in inpatient settings. Int J Epidemiol. 2016;dyw022. DOI: 10.1093/ije/dyw022 PMID: 26979985

41. Castilla J, Martínez-Artola V, Salcedo E, Martínez-Baz I, Cenoiz MG, Guevara M, et al. Vaccine effectiveness in preventing influenza hospitalizations in Navarre, Spain, 2010-2011: cohort and case-control study. Vaccine. 2012;30(2):195-200. DOI: 10.1016/j.vaccine.2011.11.024 PMID: 22100636

42. Skowronski DM, Chambers C, Sabaiduc S, De Serres G, Winter A-L, Dickinson JA, et al. A Perfect Storm: Impact of Genomic Variation and Serial Vaccination on Low Influenza Vaccine Effectiveness During the 2014-2015 Season. Clin Infect Dis. 2016;63(1):21-32. DOI: 10.1093/cid/ciw176 PMID: 27025838

43. Smith DJ, Forrest S, Ackley DH, Perelson AS. Variable efficacy of repeated annual influenza vaccination. Proc Natl Acad Sci USA. 1999;96(4):14001-6. DOI: 10.1073/pnas.96.24.14001 PMID: 10570188

44. McLean HQ, Thompson MG, Sundaram ME, Meece JK, McClure DL, Friedich TC, et al. Impact of repeated vaccination on vaccine effectiveness against influenza A(H3N2) and B during 8 seasons. Clin Infect Dis. 2016;62(10):1375-85. DOI: 10.1093/cid/ciu680 PMID: 25270645

License and copyright
This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.

This article is copyright of the authors, 2017.